Personalized T-Cell Therapy iNeo-Vac-T01 in Advanced Colorectal Cancer

The primary objective of this study is to evaluate the feasibility, safety, and efficacy of personalized T-cell therapy based on tumor neoantigens in patients with advanced colorectal cancer, so as to provide a novel individualized therapeutic strategy for such patients.

Trial Details

NCT ID
NCT07504523
Phase
PHASE1
Sponsor
Ying Yuan, MD
Status
RECRUITING
Cancer Type
Colorectal Cancer
Interventions
  • iNeo-Vac-T01
Locations (sample)
  • Hangzhou, Zhejiang, China|30.29365,120.16142

Key Eligibility Criteria

  • Aged ≥ 18 years and ≤ 70 years;
  • Patients with pathologically and radiologically confirmed advanced colorectal cancer, with at least one measurable lesion on imaging;
  • Failure of standard therapy, ineligibility for standard therapy, or refusal to receive standard therapy;
  • Expected survival of at least 6 months;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →